Prescription Drug Patches to 2015

• Publication date: August 2011

Transdermal drug patches offer the advantages of ease of use, painlessness, disposability, control of drug delivery and avoidance of first-pass metabolism by the liver. Advances in synthetic materials and patch design have led to patches that are more esthetically acceptable and that are capable of delivering sustained dosing of active compounds for several days in a smaller package. Patches relying on passive transport mechanisms have been limit...

Transdermal drug patches offer the advantages of ease of use, painlessness, disposability, control of drug delivery and avoidance of first-pass metabolism by the liver. Advances in synthetic materials and patch design have led to patches that are more esthetically acceptable and that are capable of delivering sustained dosing of active compounds for several days in a smaller package. Patches relying on passive transport mechanisms have been limited in their ability to deliver new classes of drugs, but formulations employing penetration enhancers, and patch designs incorporating microporation and energy-assisted delivery are expanding the range of drugs that can be effectively delivered transdermally. Growth in demand for drug patches is being driven by several factors – factors with strong demographic and population trend underpinnings. Further improvements to transdermal transport and the introduction of new patch designs will keep this segment expanding through 2015.


Highlights

• Analyzes and evaluates prescription skin patch products and assesses risks and market potential
• Analyzes patch designs, technologies and patch development issues
• Provides assessments of prescription skin patch products in two dozen key market segments
• Provides market data and forecasts to 2015
• Profiles patch manufacturers, their product development activities and strategies

Prescription Drug Industry

Summary of Contents
Executive Summary

The Transdermal Drug Delivery Market Dynamics

Drug Patch Market Structure
Important Patch Drug Therapies
Transdermal Drug Packaging
Demand Drivers
Competitive Landscape
Factors Limiting Growth


Prescription Patch Design & Technology

Patch Architecture
Passive Transdermal Patch Design
Passive Patch Construction
Active Transport Patch Technologies
Evolving Prescription Patch Technologies


Prescription Patch Development Factors

The Design Cycle
Design Partnerships
Patch Product Testing
Trials and Submissions
Pharmacokinetics & Dosage Forms
Patch Manufacturing Dynamics
Patch Manufacturing Company Profiles

Drugs Currently Delivered in Approved Transdermal Patches

Buprenoorphine
Clonidine
Diclofenac
Estradiol
Estradiol/Norethrindone acetate
Fentanyl
Lidocaine
Mecamylamine
Methylphenidate
Nitroglycerin
Norelgestromin
Oxybutynin
Rivastigmine
Rotigotine (EU)
Scopolamine
Selegiline
Testosterone


Drugs in Development for Transdermal Patch Delivery Systems

Antivirals
CNS
Hormones
Metabolic
Pain Management

Prescription Patch Design & Acceptance Factors

Dosing and Rate Factors
Materials Compatibility
Clinical Trial Process
Biocompatibility
Market Factors

FDA Regulations
Rx-to-OTC Switching
New Patch Technologies
Skin Patch Revenue Models

FDA-Approved Patch Therapies – Analysis and Market Data

ADHD
Contraception
Cardiovascular/Angina
Depression
Hormone Replacement Therapy
Hypertension
Motion Sickness
Neurology
Osteoporosis
Pain Management

Emerging Patch Therapeutics – Opportunity and Risk Assessment

Addiction
Neurology
Antiviral
Asthma
Oncology
Diabetes
Neurology
Reproductive Medicine
Sexual Dysfunction
Vaccines

Profiles of Market Participants